Cabergoline Side Effects Compared with Placebo

Nausea, headache, dizziness, and constipation were the most common cabergoline side effects in the 4-week placebo-controlled trial on the U.S. Food and Drug Administration (FDA) label. At Opt Health, we have a physician read every lab we order before anyone is offered a treatment. Against placebo, the rates were 27% vs 20% for nausea, 26% vs 25% for headache, 15% vs 5% for dizziness, and 10% vs 0% for constipation. The label's serious warnings cover heart-valve disease and fibrosis, and its precautions add impulse-control behaviors. The label calls for an echocardiogram before treatment and routine monitoring every 6 to 12 months.¹

Cabergoline Side Effects in the Label Trial

The FDA-approved cabergoline label reports adverse events from a 4-week, double-blind trial involving 168 people taking cabergoline and 20 taking placebo.¹

Source: 4-week double-blind, placebo-controlled trial in the cabergoline label.¹

Headache was reported by 26% of the cabergoline group and 25% of the placebo group. Asthenia was also close, at 9% with cabergoline and 10% with placebo. These differences come from a small placebo group of 20 people, so the percentages require context.

Other events showed a wider separation. Dizziness occurred in 15% of people taking cabergoline and 5% taking placebo. Constipation occurred in 10% and 0%, while nausea occurred in 27% and 20%. Fatigue and postural hypotension were each reported in the cabergoline group and absent from the placebo group.¹

The label’s efficacy trials involved hyperprolactinemic women, while its adverse-event tables cover hyperprolactinemic patients. The label provides no men-only side-effect rates.¹ A single prolactin result is one data point, while repeat results can show a pattern. If you are taking cabergoline, your physician can interpret your symptoms alongside your prolactin results and follow the pattern over time.

Heart-Valve Monitoring on Cabergoline

Heart-valve monitoring starts before cabergoline treatment. The label states that every patient should receive a cardiovascular evaluation, including an echocardiogram to assess for valvular disease.¹

An echocardiogram is an ultrasound examination of the heart. Your prescriber uses it to evaluate the structure and movement of your heart valves before treatment and during follow-up.

The label recommends routine echocardiographic monitoring every 6 to 12 months. An earlier evaluation may be indicated if you develop edema, a new cardiac murmur, shortness of breath, or congestive heart failure.¹ Report new symptoms to your prescriber so the timing of your evaluation can be adjusted.

The label directs discontinuation when an echocardiogram shows new valvular regurgitation, valvular restriction, or valve-leaflet thickening.¹ Your prescriber makes that decision after reviewing the imaging and your clinical findings.

Fibrosis and Impulse-Control Screening on Cabergoline

The cabergoline label includes postmarketing reports of pleural, pericardial, and retroperitoneal fibrosis, meaning fibrotic tissue around the lungs, heart, or structures behind the abdominal cavity.¹

A postmarketing report means the event was reported after the medication entered broader clinical use. The label does not provide an event rate for these fibrosis reports. Your medical history and any new symptoms help your prescriber decide whether further evaluation is needed.

The label also reports impulse-control and compulsive behaviors with dopamine agonists, including cabergoline. Reported behaviors include pathological gambling, increased libido, and hypersexuality.¹

These behaviors were generally reversible after a dose reduction or treatment discontinuation, according to the label.¹ A prescriber should make either change. If you or someone close to you notices a new compulsive behavior, bring it to your prescriber rather than changing treatment yourself.

For a broader discussion of uses and sexual effects, see cabergoline for men.

Medicines and Conditions That Change the Plan

Several medicines and medical conditions can change whether cabergoline is appropriate for you. The label says cabergoline should not be given concurrently with D2-antagonists such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.¹

The label also calls for care when cabergoline is used with other medicines known to lower blood pressure.¹ This matters because dizziness and postural hypotension appeared in the placebo-controlled trial.

Give your prescriber a complete list of your prescriptions before treatment begins. Your prescriber can identify a D2-antagonist or another blood-pressure-lowering medicine and decide whether the treatment plan needs to change.

The label lists the following contraindications:

• Uncontrolled hypertension or known hypersensitivity to ergot derivatives
• A history of cardiac valvular disorders
• A history of pulmonary, pericardial, or retroperitoneal fibrotic disorders¹

A contraindication is a condition in which the label says the medication should not be used. Your initial medical review should cover these conditions before a prescription is considered.

Cabergoline Elimination and Symptom Timing

Cabergoline has an elimination half-life of 63 to 69 hours based on urinary data from 12 healthy subjects.¹ A half-life describes the time required for the measured amount of a drug in the body to decrease by half.

The label connects cabergoline’s prolonged prolactin-lowering effect with its slow elimination and long half-life.¹ That finding describes how long cabergoline remains in the body. It does not establish how long nausea, headache, dizziness, or another individual side effect will last.

If you are trying to determine how long cabergoline side effects last, track when the symptom began and how it changes. Your prescriber can compare that timeline with your treatment history and decide whether further evaluation is appropriate.

Cabergoline Tolerability Next to Bromocriptine

A comparative 8-week study reported fewer adverse-event discontinuations with cabergoline than with bromocriptine. Cabergoline was discontinued because of an adverse event in 4 of 221 patients, or 2%. Bromocriptine was discontinued in 14 of 231 patients, or 6%.¹

The most common reasons for stopping cabergoline were headache, nausea, and vomiting.¹ These discontinuation numbers describe what happened in that study. They do not determine which medication fits your medical history or treatment goals.

The full medication decision involves more than one tolerability result. See cabergoline vs bromocriptine for the broader comparison, then review your prolactin results and symptoms with your prescriber.

The Opt Take on Cabergoline Side Effects

Cabergoline monitoring works best when a physician reads your symptoms, medical history, prolactin results, and follow-up data together. One symptom is a data point. A change in symptoms alongside a change in prolactin gives your physician more context for the next decision.

At Opt Health, we begin with a blood panel covering more than 55 biomarkers. An Opt Health physician reviews those results in a one-on-one consultation and builds a plan around your numbers, current medicines, symptoms, and goals.

Treatment monitoring continues after the first prescription. Labs and physician consultations repeat every 3 to 4 months, allowing the plan to change when your numbers or symptoms change. If cabergoline side effects appear, your physician has a baseline and follow-up pattern to review.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.